Telmisartan-Induced Myotoxicity in Patients with Essential Hypertension
Turk Kardiyol Dern Ars. 2024 Apr;52(3):217-219. doi: 10.5543/tkda.2023.22893.ABSTRACTDrug-related muscular adverse effects are relatively common among certain groups of drugs, such as statins and steroids. However, these adverse effects are less well-known for angiotensin receptor blockers (ARBs). It is proposed that telmisartan and irbesartan may cause myotoxicity via increased Peroxisome Proliferator-Activated Receptor gamma (PPAR-gamma) activity. Herein, we present two hypertensive patients in whom telmisartan-induced myotoxicity was observed. Therefore, physicians should be aware that telmisartan, along with some other...
Source: Turk Kardiyoloji Dernegi arsivi - April 4, 2024 Category: Cardiology Authors: S üleyman Cihan Kara U ğur Canpolat Source Type: research
Telmisartan-Induced Myotoxicity in Patients with Essential Hypertension
Turk Kardiyol Dern Ars. 2024 Apr;52(3):217-219. doi: 10.5543/tkda.2023.22893.ABSTRACTDrug-related muscular adverse effects are relatively common among certain groups of drugs, such as statins and steroids. However, these adverse effects are less well-known for angiotensin receptor blockers (ARBs). It is proposed that telmisartan and irbesartan may cause myotoxicity via increased Peroxisome Proliferator-Activated Receptor gamma (PPAR-gamma) activity. Herein, we present two hypertensive patients in whom telmisartan-induced myotoxicity was observed. Therefore, physicians should be aware that telmisartan, along with some other...
Source: Turk Kardiyoloji Dernegi arsivi - April 4, 2024 Category: Cardiology Authors: S üleyman Cihan Kara U ğur Canpolat Source Type: research
Telmisartan-Induced Myotoxicity in Patients with Essential Hypertension
Turk Kardiyol Dern Ars. 2024 Apr;52(3):217-219. doi: 10.5543/tkda.2023.22893.ABSTRACTDrug-related muscular adverse effects are relatively common among certain groups of drugs, such as statins and steroids. However, these adverse effects are less well-known for angiotensin receptor blockers (ARBs). It is proposed that telmisartan and irbesartan may cause myotoxicity via increased Peroxisome Proliferator-Activated Receptor gamma (PPAR-gamma) activity. Herein, we present two hypertensive patients in whom telmisartan-induced myotoxicity was observed. Therefore, physicians should be aware that telmisartan, along with some other...
Source: Turk Kardiyoloji Dernegi arsivi - April 4, 2024 Category: Cardiology Authors: S üleyman Cihan Kara U ğur Canpolat Source Type: research
Telmisartan-Induced Myotoxicity in Patients with Essential Hypertension
Turk Kardiyol Dern Ars. 2024 Apr;52(3):217-219. doi: 10.5543/tkda.2023.22893.ABSTRACTDrug-related muscular adverse effects are relatively common among certain groups of drugs, such as statins and steroids. However, these adverse effects are less well-known for angiotensin receptor blockers (ARBs). It is proposed that telmisartan and irbesartan may cause myotoxicity via increased Peroxisome Proliferator-Activated Receptor gamma (PPAR-gamma) activity. Herein, we present two hypertensive patients in whom telmisartan-induced myotoxicity was observed. Therefore, physicians should be aware that telmisartan, along with some other...
Source: Turk Kardiyoloji Dernegi arsivi - April 4, 2024 Category: Cardiology Authors: S üleyman Cihan Kara U ğur Canpolat Source Type: research
Telmisartan-Induced Myotoxicity in Patients with Essential Hypertension
Turk Kardiyol Dern Ars. 2024 Apr;52(3):217-219. doi: 10.5543/tkda.2023.22893.ABSTRACTDrug-related muscular adverse effects are relatively common among certain groups of drugs, such as statins and steroids. However, these adverse effects are less well-known for angiotensin receptor blockers (ARBs). It is proposed that telmisartan and irbesartan may cause myotoxicity via increased Peroxisome Proliferator-Activated Receptor gamma (PPAR-gamma) activity. Herein, we present two hypertensive patients in whom telmisartan-induced myotoxicity was observed. Therefore, physicians should be aware that telmisartan, along with some other...
Source: Turk Kardiyoloji Dernegi arsivi - April 4, 2024 Category: Cardiology Authors: S üleyman Cihan Kara U ğur Canpolat Source Type: research
Telmisartan-Induced Myotoxicity in Patients with Essential Hypertension
Turk Kardiyol Dern Ars. 2024 Apr;52(3):217-219. doi: 10.5543/tkda.2023.22893.ABSTRACTDrug-related muscular adverse effects are relatively common among certain groups of drugs, such as statins and steroids. However, these adverse effects are less well-known for angiotensin receptor blockers (ARBs). It is proposed that telmisartan and irbesartan may cause myotoxicity via increased Peroxisome Proliferator-Activated Receptor gamma (PPAR-gamma) activity. Herein, we present two hypertensive patients in whom telmisartan-induced myotoxicity was observed. Therefore, physicians should be aware that telmisartan, along with some other...
Source: Turk Kardiyoloji Dernegi arsivi - April 4, 2024 Category: Cardiology Authors: S üleyman Cihan Kara U ğur Canpolat Source Type: research
Telmisartan-Induced Myotoxicity in Patients with Essential Hypertension
Turk Kardiyol Dern Ars. 2024 Apr;52(3):217-219. doi: 10.5543/tkda.2023.22893.ABSTRACTDrug-related muscular adverse effects are relatively common among certain groups of drugs, such as statins and steroids. However, these adverse effects are less well-known for angiotensin receptor blockers (ARBs). It is proposed that telmisartan and irbesartan may cause myotoxicity via increased Peroxisome Proliferator-Activated Receptor gamma (PPAR-gamma) activity. Herein, we present two hypertensive patients in whom telmisartan-induced myotoxicity was observed. Therefore, physicians should be aware that telmisartan, along with some other...
Source: Turk Kardiyoloji Dernegi arsivi - April 4, 2024 Category: Cardiology Authors: S üleyman Cihan Kara U ğur Canpolat Source Type: research
An injectable polyacrylamide/chitosan-based hydrogel with highly adhesive, stretchable and electroconductive properties loaded with irbesartan for treatment of myocardial ischemia-reperfusion injury
In conclusion, our results suggest that the P-DNAH hydrogel, possessing suitable mechanical properties and electroconductivity, serves as an ideal IECH for DDS, delivering irbesartan to promote heart repair.PMID:38552696 | DOI:10.1016/j.ijbiomac.2024.131175 (Source: International Journal of Biological Macromolecules)
Source: International Journal of Biological Macromolecules - March 29, 2024 Category: Biochemistry Authors: Shasha Zhu Wei Zhang Chunming Xu Jie Huang Cao Zou Source Type: research
Sparsentan in immunoglobulin A nephropathy: a profile of its use
AbstractSparsentan (FILSPARI®), an oral, dual endothelin and angiotensin receptor antagonist, is an emerging new treatment option for patients with immunoglobulin A (IgA) nephropathy. Sparsentan received accelerated approval in the USA for the treatment of adults with IgA nephropathy who are at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UP/C) ≥ 1.5 g/g, as well as a positive opinion recommending approval in the EU. In the ongoing phase 3 PROTECT trial in adults with IgA nephropathy, sparsentan was associated with favourable antiproteinuric effects, which were maintained over 110 ...
Source: Drugs and Therapy Perspectives - March 29, 2024 Category: Drugs & Pharmacology Source Type: research
The protective effects of Irbesartan in cognitive impairment in hypertension
Aging (Albany NY). 2024 Mar 23;16. doi: 10.18632/aging.205589. Online ahead of print.ABSTRACTVascular cognitive impairment (VCI) is claimed as the second most common type of dementia after Alzheimer's disease (AD), in which hypertension is a critical inducer. Currently, hypertension-induced cognitive impairment lacks clinical treatments. Irbesartan is a long-acting angiotensin receptor antagonist with promising antihypertensive properties. Our research will focus on the potential function of Irbesartan on hypertension-induced cognitive impairment. Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats were orally dos...
Source: Aging - March 25, 2024 Category: Biomedical Science Authors: Shengyun Hao Qian He Yuan Yuan Qiong Mu Source Type: research
The protective effects of Irbesartan in cognitive impairment in hypertension
Aging (Albany NY). 2024 Mar 23;16. doi: 10.18632/aging.205589. Online ahead of print.ABSTRACTVascular cognitive impairment (VCI) is claimed as the second most common type of dementia after Alzheimer's disease (AD), in which hypertension is a critical inducer. Currently, hypertension-induced cognitive impairment lacks clinical treatments. Irbesartan is a long-acting angiotensin receptor antagonist with promising antihypertensive properties. Our research will focus on the potential function of Irbesartan on hypertension-induced cognitive impairment. Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats were orally dos...
Source: Aging - March 25, 2024 Category: Biomedical Science Authors: Shengyun Hao Qian He Yuan Yuan Qiong Mu Source Type: research
The protective effects of Irbesartan in cognitive impairment in hypertension
Aging (Albany NY). 2024 Mar 23;16. doi: 10.18632/aging.205589. Online ahead of print.ABSTRACTVascular cognitive impairment (VCI) is claimed as the second most common type of dementia after Alzheimer's disease (AD), in which hypertension is a critical inducer. Currently, hypertension-induced cognitive impairment lacks clinical treatments. Irbesartan is a long-acting angiotensin receptor antagonist with promising antihypertensive properties. Our research will focus on the potential function of Irbesartan on hypertension-induced cognitive impairment. Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats were orally dos...
Source: Aging - March 25, 2024 Category: Biomedical Science Authors: Shengyun Hao Qian He Yuan Yuan Qiong Mu Source Type: research
Irbesartan ameliorates diabetic nephropathy by activating the Nrf2/Keap1 pathway and suppressing NLRP3 inflammasomes in vivo and in vitro
CONCLUSIONS: Our results suggested that IRB ameliorates diabetic nephropathy by activating the Nrf2/Keap1 pathway and suppressing the NLRP3 inflammasomes in vivo and in vitro. These findings provide new therapeutic strategies of diabetic nephropathy.PMID:38503013 | DOI:10.1016/j.intimp.2024.111844 (Source: International Immunopharmacology)
Source: International Immunopharmacology - March 19, 2024 Category: Allergy & Immunology Authors: Yuan Li Weihong Long Haifeng Zhang Meng Zhao Menghan Gao Weiying Guo Lu Yu Source Type: research
Irbesartan ameliorates diabetic nephropathy by activating the Nrf2/Keap1 pathway and suppressing NLRP3 inflammasomes in vivo and in vitro
CONCLUSIONS: Our results suggested that IRB ameliorates diabetic nephropathy by activating the Nrf2/Keap1 pathway and suppressing the NLRP3 inflammasomes in vivo and in vitro. These findings provide new therapeutic strategies of diabetic nephropathy.PMID:38503013 | DOI:10.1016/j.intimp.2024.111844 (Source: International Immunopharmacology)
Source: International Immunopharmacology - March 19, 2024 Category: Allergy & Immunology Authors: Yuan Li Weihong Long Haifeng Zhang Meng Zhao Menghan Gao Weiying Guo Lu Yu Source Type: research
Growth “self-inhibition” of irbesartan desmotrope: surface intra-annular tautomer inter-conversion is the culprit
Chem. Commun., 2024, Advance Article DOI: 10.1039/D3CC06170A, CommunicationXiang Kang, Mingtao Zhang, Weiwei Tang, Junbo Gong The dynamic intra-annular tautomerism on the surface (Path II) is essential for producing the “self-inhibited” growth phenomenon of irbesartan desmotrope. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - Chem. Commun. latest articles)
Source: RSC - Chem. Commun. latest articles - February 27, 2024 Category: Chemistry Authors: Xiang Kang Source Type: research
